AW, D., & M, B. (2026). Cost-Utility Analysis of Calcitonin Gene-Related Peptide Monoclonal Antibodies for Patients with Episodic Migraine Headache in the USA. PharmacoEconomics. https://doi.org/10.1007/s40273-026-01624-1
Chicago Style (17th ed.) CitationAW, Dong, and Bounthavong M. "Cost-Utility Analysis of Calcitonin Gene-Related Peptide Monoclonal Antibodies for Patients with Episodic Migraine Headache in the USA." PharmacoEconomics 2026. https://doi.org/10.1007/s40273-026-01624-1.
MLA (9th ed.) CitationAW, Dong, and Bounthavong M. "Cost-Utility Analysis of Calcitonin Gene-Related Peptide Monoclonal Antibodies for Patients with Episodic Migraine Headache in the USA." PharmacoEconomics, 2026, https://doi.org/10.1007/s40273-026-01624-1.
Warning: These citations may not always be 100% accurate.
